Daegu, South Korea

Jaetae Lee

This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Kyungpook National University Industry-Academic Cooperation Foundation, Daegu-Gyeongbuk Medical Innovation Foundation. Active years: 2021-2022.

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2021-2022

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Jaetae Lee: Innovator in Pharmaceutical Chemistry

Introduction

Jaetae Lee is a prominent inventor based in Daegu, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on aryl ethene derivatives.

Latest Patents

Jaetae Lee holds 2 patents, with his latest inventions focusing on an aryl ethene derivative and a pharmaceutical composition containing the same as an active ingredient. These inventions aim to inhibit the activity of the estrogen-related receptor gamma (ERRγ), showcasing his commitment to advancing medical science.

Career Highlights

Throughout his career, Jaetae Lee has been associated with notable institutions, including the Kyungpook National University Industry-Academic Cooperation Foundation and the Daegu-Gyeongbuk Medical Innovation Foundation. His work in these organizations has allowed him to further his research and development in pharmaceutical innovations.

Collaborations

Jaetae Lee has collaborated with esteemed colleagues, including Sung Yeoun Hwang and Sung Jin Cho. These partnerships have contributed to the success of his research endeavors.

Conclusion

Jaetae Lee's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor in the field. His work continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…